Evaluating eye tissue thickness in healthy individuals and those with certain eye diseases

A Multicenter, Cross-sectional Study to Describe the Conjunctiva and Tenon's Capsule Status of Healthy Subjects and nAMD/DME Patients Followed in Clinical Practice in Spain

Observational Hoffmann-La Roche · NCT06723288

This study is testing how thick certain eye tissues are in people with specific eye diseases and comparing them to healthy individuals to learn more about their eye health.

Quick facts

Study typeObservational
Enrollment854 (estimated)
Ages45 Years and up
SexAll
SponsorHoffmann-La Roche Industry-sponsored
Locations14 sites (Oviedo, Asturias and 13 other locations)
Trial IDNCT06723288 on ClinicalTrials.gov

What this trial studies

This observational study aims to measure the thickness of the conjunctiva and Tenon's capsule in participants diagnosed with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), as well as in age-matched healthy subjects. Using spectral domain-optical coherence tomography (SD-OCT), the study will gather in vivo measurements to better understand the differences in eye tissue among these groups. The findings may provide insights into the ocular health of individuals with these conditions compared to healthy individuals.

Who should consider this trial

Good fit: Ideal candidates include individuals diagnosed with nAMD or DME, as well as healthy subjects with normal visual function.

Not a fit: Patients with a history of ocular surgery, certain eye diseases, or those currently undergoing treatment for glaucoma may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance the understanding of ocular changes in patients with nAMD and DME, potentially leading to improved diagnostic and treatment strategies.

How similar studies have performed: While this approach is observational and may have been explored in other contexts, the specific focus on conjunctiva and Tenon's capsule thickness in these conditions is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

For nAMD/DME participants:

- Diagnosis of nAMD/DME

For healthy subjects:

- Normal visual function

Exclusion Criteria:

* Current or past treatment for glaucoma (only for healthy subjects)
* Dry eye disease except those treated only with artificial tears
* Ocular hypertension treated with hypotensive drugs
* Pterygium
* Strabismus
* Previous ocular surgery except cataract surgery
* Cataract surgery with scleral incision
* Current contact lens wearers
* Myopia with more than 6 diopters
* Corneal transplant
* History of ocular surface inflammation
* Active or recent conjunctivitis infection
* Pregnancy
* Participant who has already received an IVT injection in the superotemporal quadrant (only for nAMD/DME participants)

Where this trial is running

Oviedo, Asturias and 13 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Neovascular Age-related Macular DegenerationDiabetic Macular Edema
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.